PET分子显像在非小细胞肺癌表皮生长因子受体突变检测中的研究进展  

The progresses in PET molecular imaging in the detection of epidermal growth factor receptor mutations in non-small cell lung cancer

作　　者：吴思敏 周瑞 吴爽[1] 田梅[1] Wu Simin;Zhou Rui;Wu Shuang;Tian Mei(PET Center,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China)

机构地区：[1]浙江大学医学院附属第二医院PET中心,杭州310009

出　　处：《国际放射医学核医学杂志》2019年第6期576-581,共6页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：肺癌是最常见的恶性肿瘤之一,其中非小细胞肺癌(NSCLC)约占肺癌的85%。对于无法进行手术的晚期NSCLC患者,如果能够明确病灶具有表皮生长因子受体(EGFR)突变,采用针对EGFR突变位点的靶向药物能明显改善患者的预后。但是对于不能行手术及穿刺活检的患者,难以通过获取病理组织检测病灶的EGFR突变状态,因此临床上对NSCLC患者EGFR突变的无创活体检测具有较大需求。目前临床上广泛使用的PET分子显像技术可选用针对EGFR突变的特异性示踪剂,具有巨大潜力。笔者主要针对各种示踪剂PET分子显像在EGFR突变检测中的研究进展进行综述。Lung cancer is one of the most common types of malignancy.Non-small cell lung cancer(NSCLC)accounts for 85%of lung cancer cases.Epidermal growth factor receptor(EGFR)targeted therapy can significantly improve the prognosis of patients with advanced NSCLC.In this case,determining EGFR mutation status is critical in selecting an optimal treatment regimen for these patients.However,the acquisition of good-quality tumor tissues for genetic alteration analysis remains a challenge for patients who cannot bear surgery and biopsy.Therefore,noninvasive in vivo diagnosis of EGFR mutation status in NSCLC patients is critical for patient management.Positron emission tomography(PET)with specific probe targeted to EGFR has the potential to fulfill this requirement.This study provides a brief review of the value of PET with multiple tracers in predicting the status of EGFR mutation.

关 键 词：正电子发射断层显像术 癌 非小细胞肺 受体 表皮生长因子 

分 类 号：R734[医药卫生—肿瘤]